R.E.D. Laboratories

FlandersBio on Twitter

Galapagos NV: business update: http://t.co/6w1jppWE

posted 3 days ago

Social Media

Life Sciences Database

in het nederlands

FlandersBio offers an up-to-date life sciences database containing all the life sciences companies with biotech activity in Flanders, and all FlandersBio members. The guide provides easy and fast access to the local life sciences community.

Website: http://www.redlabs.be
Email:
Phone: +32 2 481 53 10
FlandersBio Member
More address details

Business Focus

R.E.D. Laboratories develops clinical diagnostic tests and therapeutics for chronic immune diseases, such as Multiple Sclerosis (MS) and Chronic Fatigue Syndrome (CFS). The company’s scientific platform is based on investigating the interferon system, the key antiviral defence mechanism of the body.

Company Profile

R.E.D. Laboratories is a Belgian biotechnology company developing clinical diagnostic tests and therapeutics for chronic immune diseases, such as Multiple Sclerosis (MS) and Chronic Fatigue Syndrome (CFS).

The company's scientific platform is based on investigating the interferon system, the key antiviral defence mechanism of the body.

The company is targeting recently discovered cell abnormalities for new drug development as well as developing clinical assays to diagnose, stage and monitor these diseases.

Science & Technology or Services

R.E.D. Laboratories has an in-house research team that focuses its energies and resources in the analysis of the biochemical, molecular, and cellular pathways that are disrupted in chronic immune disease. The result of this effort is that the company has identified numerous diagnostic markers for other chronic immune diseases such as Multiple Sclerosis (MS) and cancer, and in addition has identified, tested and filed patent applications on new drugs to treat CFS and MS.

The company is currently in discussions with a number of clinical laboratory companies throughout the world to transfer its diagnostic tests and technology. In therapeutics, Phase I clinical trials are expected to begin in late 2002 to test new compounds in patients with MS and in those with CFS.